RYZ801
Phase 1Small molecule
RYZ801 is one of 21 small molecule programs targeting Unresectable. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Unresectable
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Tecentriq
RochePhase 3
Lenvima
EisaiPhase 2
Vitrakvi
BayerPhase 2
Tagrisso
AstraZenecaPhase 2
Camptosar
PfizerPhase 2
Tafinlar
NovartisPhase 2
Zegfrovy
DDizal Pharmaceuticals
Phase 2
Xalkori
PPrism Pharmaceuticals
Phase 2
Ensacove
XXcovery Holdings, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RYZ801. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRayzeBio, Inc.